Core Viewpoint - NeoGenomics, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026, prior to the U.S. market opening, with a subsequent webcast and conference call scheduled for discussion [1]. Company Overview - NeoGenomics, Inc. is a leading cancer diagnostics company that specializes in cancer genetics testing and information services, providing a comprehensive oncology-focused testing menu [3]. - The company serves a variety of clients including oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms, offering innovative diagnostic and predictive testing to aid in cancer diagnosis and treatment [3]. - Headquartered in Fort Myers, Florida, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories across the U.S. and a CAP-accredited laboratory in Cambridge, United Kingdom [3].

Core Insights - NeoGenomics, Inc. announced preliminary fourth quarter and full-year 2025 revenue, indicating a commitment to being the preferred cancer testing partner for pathologists and oncologists [2][6] - The company expects fourth quarter revenue of approximately $190 million, reflecting an 11% year-over-year growth, and full-year revenue of approximately $727 million, representing a 10% year-over-year growth [6] Revenue Summary - For the fourth quarter of 2025, NeoGenomics anticipates total revenue of around $190 million, which is an 11% increase compared to the previous year [6] - The projected total revenue for the full year 2025 is approximately $727 million, showing a 10% growth year-over-year [6] CFO Transition - NeoGenomics announced a succession plan for its Chief Financial Officer, with Abhishek Jain joining as Executive Vice President on January 12, 2026, and transitioning to CFO on March 2, 2026 [3][4] - Current CFO Jeff Sherman will retire on April 14, 2026, after ensuring a smooth transition [3][4] Leadership Insights - Abhishek Jain has a strong background in guiding life sciences companies through growth and transformation, and he aims to enhance financial discipline and operational efficiency at NeoGenomics [4] - Jeff Sherman expressed confidence in the company's ability to innovate in therapy selection and minimal residual disease (MRD) testing, particularly in community settings [4]